Results 11 to 20 of about 3,980,763 (249)

Progressive retinal detachment secondary to juxtapapillary microholes in association with type 3 posterior staphylomas

Clinical Ophthalmology, 2014
Christiana B Dinah,1 Daniela Vaideanu-Collins,2 David HW Steel1,31Ophthalmology Department, Sunderland Eye Infirmary, Sunderland, 2Ophthalmology Department, James Cook University Hospital, Middlesbrough, UK, 3Institute of Genetic Medicine, Newcastle ...
Dinah CB, Vaideanu-Collins D, Steel DHW
doaj   +1 more source

Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

Journal of Neuroinflammation, 2022
There are over 15 disease-modifying drugs that have been approved over the last 20 years for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited treatment options available for progressive MS.
Emily Kamma, Wendy Lasisi, Cole Libner, Huah Shin Ng, Jason R. Plemel   +4 more
doaj   +1 more source

Primary and Secondary Progressive Aphasia in Posterior Cortical Atrophy

Life, 2022
Background: Posterior cortical atrophy (PCA) is a clinico-radiological syndrome characterized by a progressive decline in visuospatial/visuoperceptual processing.
Catherine Brodeur, Émilie Belley, Lisa-Marie Deschênes, Adriana Enriquez-Rosas, Michelyne Hubert, Anik Guimond, Josée Bilodeau, Jean-Paul Soucy, Joël Macoir   +8 more
doaj   +1 more source

The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report

Consilium Medicum, 2023
Siponimod (Kajendra) is a sphingosine-1-phosphate receptor modulator type 1 and 5 (S1P1,5), the first targeted agent for the treatment of patients with secondary progressive multiple sclerosis, both with and without exacerbations and/or activity ...
Denis S. Korobko, Ivan Ie. Arkhipov, Anna I. Prokaeva, Ekaterina V. Tret'iakova   +3 more
doaj   +1 more source

Rapidly progressive pleuro-parenchymal fibroelastosis secondary to cyclophosphamide chemotherapy

Indian Journal of Medical and Paediatric Oncology, 2020
Pleuroparenchymal fibroelastosis (PPFE) is a rare progressive interstitial lung disease presenting with predominantly upper-lobe pleural thickening and pulmonary fibrosis.
Maheema Bhaskar, Owais Tisekar, Sandeep Tandon, Tushar Vora, Bhavin Jankharia   +4 more
doaj   +1 more source

Progressive optic neuropathy secondary to JAK2 mutation-positive myeloproliferative neoplasm

Indian Journal of Ophthalmology. Case Reports, 2022
We describe a 25-year-old male presenting with chronic papilledema due to cerebral venous sinus thrombosis (CVST) and was found to have a myeloproliferative disorder with JAK2 mutation. All measures to salvage vision were unfruitful from transverse sinus
Swetha Komma, Selvakumar Ambika, Veena O Noronha, Deepak Arjundas   +3 more
doaj   +1 more source

Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a. [PDF]

, 2004
S100B belongs to a family of calcium-binding proteins implicated in intracellular and extracellular regulatory activities. This study of serum S100B in primary progressive multiple sclerosis (PPMS) is based on data obtained from a randomized, controlled ...
Lim, Ee Tuan, Leary, Siobhan M, Geoff Keir, Petzold, Axel, Thompson, Alan J, Gavin Giovannoni, Siobhan M Leary, Altmann, Daniel R, Keir, Geoff, Ee Tuan Lim, David H Miller, Ed J Thompson, Giovannoni, Gavin, Miller, David H, Alan J Thompson, Daniel R Altmann, Thompson, Ed J, Axel Petzold   +17 more
core   +2 more sources

Comparison of medical and social characteristics and quality of life of patients with primary- and secondary-progressive multiple sclerosis

Неврология, нейропсихиатрия, психосоматика, 2021
Management of patients with secondary progressive multiple sclerosis (SPMS) remains one of the most challenging tasks of modern neurology. Patients with SPMS present with more severe neurological symptoms, increased hospitalization frequency, pronounced ...
Ya. V. Vlasov, N. G. Polyarnaya, A. N. Boyko   +2 more
doaj   +1 more source

Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS [PDF]

, 2012
Despite significant progress in the development of therapies for relapsing MS, progressive MS remains comparatively disappointing. Our objective, in this paper, is to review the current challenges in developing therapies for progressive MS and identify ...
Salvetti, M, D. Brown, T. Coetzee, K. Sharrock, Lee, K, Brown, D, Feinstein, A, Thompson, A, K. Zuidwijk, D. Chandraratna, Kapoor, R, Fox, RJ, Zuidwijk, K, K. Lee, A. Thompson, G. Comi, Toosy, A, Baneke, P, Browne, P, Sharrock, K, O. Ciccarelli, P. Browne, A. Feinstein, Comi, G, R. J. Fox, Chandraratna, D, P. Zaratin, Baker, D, R. Kapoor, Ciccarelli, O, Zaratin, P, P. Baneke, Coetzee, T, D. Baker, SALVETTI, Marco, A. Toosy   +35 more
core   +1 more source

Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective This study assessed whether upper cervical cord area (UCCA) measured on routine brain MRI can serve as a biomarker of conversion to SPMS. Methods This is a single‐center retrospective cohort study of RRMS patients with cross‐sectional and longitudinal analyses of clinical and MRI data. Future SPMS converters were matched by age, sex,
El Ayoubi NK, Al Ghazal S, Hannoun S, Siddik MA, Najjar NM, Dagher J, Abboud J, Semaan MG, Khoury SJ.   +8 more
europepmc   +2 more sources